Tag: kinase inhibition assay

Development of a Robust Automated 384-well Whole Blood Flow Cytometry Assay

Flow CAST®Kinase Inhibition Assay Citation: Wise S. et al. Development of a Robust Automated 384-well Whole Blood Flow Cytometry Assay. SLAS 2014. 3rd Annual Conference & Exhibition. January 18-22, 2014. San Diego, CA Highlights from this Poster "Monitoring basophil activation in whole blood via flow cytometry is an accurate method for measuring a pharmacodynamic response

BUHLMANN announces new Microsite for Kinase Inhibition Assay

BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYK pathways are a large focus for pharmaceutical

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Tag: kinase inhibition assay

Development of a Robust Automated 384-well Whole Blood Flow Cytometry Assay

BUHLMANN announces new Microsite for Kinase Inhibition Assay

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US